Full Access
INHERITED DEFICIENCIES OF COMPLEMENT PROTEINS
with special reference to congenital deficiency of the regulatory protein factor I
JENS MøLLER RASMUSSEN,
JENS MøLLER RASMUSSEN
Odense University, Campusvej 55, DK-5230 Odense M, Denmark.
Search for more papers by this authorJENS MøLLER RASMUSSEN,
JENS MøLLER RASMUSSEN
Odense University, Campusvej 55, DK-5230 Odense M, Denmark.
Search for more papers by this author
References
- 1 Mollnes TE, Lachmann PJ. Regulation of complement. Scand J Immunol 1988; 27: 127–42.
- 2 Ellison RT, Kohler PF, Curd JG, Judson FN, Reller LB. Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N Engl J Med 1983; 308: 913–6.
- 3 Merino J., Rodriquez-Valverde V., Lamelas JA, Riestra JL, Casanueva B. Prevalence of deficits of complement components in patients with recurrent meningococcal infections. J Infect Dis 1983; 148: 331.
- 4 Ross SC, Densen P. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency. Medicine 1984; 63: 243–73.
- 5 Ziccardi RJ, Cooper NR. Activation of C1 and the classical pathway of complement. In ER Podack (ed): Cytolytic lymphocytes and complement effectors of the immune system. CRC Press Inc, Florida, USA 1988, vol. 1, 21–40.
- 6 Müller-Eberhard HJ. Molecular organization and function of the complement system Ann Rev Biochem 1988; 57: 321–47.
- 7 Law SK, Lichtenberg NA, Holcombe FH, Levine RP. Interaction between the labile binding site of the fourth (C4) and fifth (C5) human complement proteins and erythrocyte cell membranes. J Immunol 1980; 125: 634–9.
- 8 Law SK, Lichtenberg NA, Levine RP. Covalent binding and hemolytic activity of complement proteins. Proc Natl Acad Sci USA 1980; 77: 7194–8.
- 9 Pangburn MK, Müller-Eberhard HJ. Relation of a putative thiolester bond in C3 to activation of the alternative pathway and binding of C3b to biological targets of complement. J Exp Med 1980; 152: 1102–14.
- 10 Tack BF, Harrison RA, Janatova J., Thomas ML, Prahl JW. Evidence for presence of an internal thiolester bond in the third component of human complement. Proc Natl Acad Sci USA 1980; 77: 5764–8.
- 11 Law SK, Levine RP. Interaction between the third complement protein and cell-surface macromolecules. Proc Natl Acad Sci USA 1977; 74: 2701–5.
- 12 Law SK, Lichtenberg NA, Levine RP. Evidence for an ester linkage between the labile binding site of C3b and receptive surfaces. J Immunol 1979; 123: 1388–94.
- 13 Sim RB, Twose TM, Paterson DS, Sim E. The covalent binding reaction of complement component C3. Biochem J 1981; 193: 115–27.
- 14 Müller-Eberhard HJ, Dalmasso AP, Calcott MA. The reaction mechanism of β1C-globulin (C3) in immune hemolysis. J Exp Med 1966; 123: 33–54.
- 15 Mardiney MR, Müller-Eberhard HJ, Feldman JD. Ultrastructural localization of the third and fourth components of complement on complement-cell complexes. Am J Pathol 1968; 53: 253–60.
- 16 Pangburn MK. Initiation and activation of the alternative pathway of complement. In ER Podack (ed): Cytolytic lymphocytes and complement effectors of the immune system. CRC Press Inc, Florida, USA 1988, vol. 1, 41–56.
- 17 Pangburn MK, Müller-Eberhard HJ. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem J 1986; 235: 723–730.
- 18 Fearon DT, Austen KF. Properdin: Binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med 1975; 142: 856–63.
- 19 Medicus RG, Götze O., Müller-Eberhard HJ. Alternative pathway of complement: Recruitment of precursor properdin by the labile C3/C5 convertase and potentiation of the pathway. J Exp Med 1976; 144: 1076–93.
- 20 Fishelson Z., Müller-Eberhard HJ. C3 convertase of human complement: enhanced formation and stability of the enzyme generated with nickel instead of magnesium. J Immunol 1982; 129: 2603–7.
- 21 Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J Exp Med 1981; 154: 856–67.
- 22 Pangburn MK, Müller-Eberhard HJ. Complement C3 convertase: cell surface restriction of β1H control and generation of restriction on neuraminidase treated cells. Proc Natl Acad Sci USA 1978; 75: 2416–20.
- 23 Fearon DT. Regulation by membrane sialic acid of β1H dependent decay dissociation of the amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci USA 1979; 75: 1971–5.
- 24 Kazatchkine MD, Fearon DT, Austen KF. Human alternative complement pathway: membrane associated sialic acid regulates the competition between B and β1H for cell bound C3b. J Immunol 1979; 122: 75–81.
- 25 Holers VM, Cole JL, Lublin DM, Seya T., Atkinson JP. Human C3b- and C4b-regulatory proteins: a new multi-gene family. Immunology Today 1985; 6: 188–92.
- 26 Hourcade D., Holers VM, Atkinson JP. The regulators of complement activation (RCA) gene cluster. Adv Immunol 1989; 45: 381–416.
- 27 Nagaki K., Iida K., Inai S. The inactivator of the first component of human complement (C1INA*). The complex formation with activated the activated first component of human complement (C1) or with its subcomponents. Int Arch Allergy Appl Immunol 1974; 46: 935–48.
- 28 Laurell AB, Johnson U., Martensson U., Sjöholm AG. Formation of complexes composed of C1r*, C1s and C1 inactivator in human serum on activation of C1. Acta Path Microbiol Scand Sect C 1978; 86: 299–306.
- 29 Ziccardi RJ. A new role for C1-inhibitor in homeostasis: Control of activation of the first component of human complement. J Immunol 1982; 128: 2505–8.
- 30 Ahearn JM, Fearon DT. Structure and function of the complement receptors CR1 (CD35) and CR2 (CD21). Adv Immunol 1989; 46: 183–219.
- 31 Scharfstein J., Ferreira A., Gigli I., Nussenzweig V. Human C4-binding protein. I: Isolation and characterization. J Exp Med 1978; 148: 207–22.
- 32 Fujita T., Tamura N. Interaction of C4-binding protein with cell-bound C4b. J Exp Med 1983; 157: 1239–51.
- 33 Fujita T., Gigli I., Nussenzweig V. Human C4-binding protein. II. Role in proteolysis of C4b by C3b inactivator. J Exp Med 1979; 123: 1195–1204.
- 34 Whaley K., Ryddy S. Modulation of the alternative complement pathway by β1H globulin. J Exp Med 1976; 144: 1147–63.
- 35 Weiler JM, Daha MR, Austen KF, Fearon DT. Control of the amplification convertase of complement by the plasma protein β1H. Proc Natl Acad Sci USA 1976; 73: 3268–72.
- 36 Pangburn MK, Schreiber RD, Müller-Eberhard HJ. Human complement C3b inactivator: isolation, characterization and demonstration of an abolute requirement for the serum protein β1H for cleavage of C3b and C4b in solution. J Exp Med 1977; 146: 257–70.
- 37 Malhotra V., Sim RB. Expression of complement factor H on the cell surface of the human monocytic cell line U937. Eur J Immunol 1985; 15: 935–41.
- 38 Schultz TF, Schreiner D., Alsenz J., Lambris JD, Dierich MP. Use of monoclonal antibodies against factor H to investigate the role of a membrane associated protein antigenically related to H in C3b-receptor function. J Immunol 1984; 132: 392–8.
- 39 Nicholson-Weller A., Burge J., Fearon DT, Weier PF, Austen KF. Isolation of a human erythrocyte membrane glycoprotein with decay accelerating activity for C3-convertases of the complement system. J Immunol 1982; 129: 184–9.
- 40 Kinoshita T., Medof ME, Silber R., Nussenzweig V. Distribution of decay accelerating factor in the peripheral blood of normal individuals and patients with paroxystic nocturnal hemoglobinuria. J Exp Med 1985; 162: 72–622.
- 41 Lublin DM, Atkinson JP. Decay-accelerating factor: Biochmistry, molecular biology and function. Annu Rev Immunol 1989; 7: 35–58.
- 42 Fujita T., Inoue T., Ogawa K., Iida K., Tamura N. The mechanism of action of decay-accelerating factor (DAF): DAF inhibits the assembly of C3 convertases by dissociating C2a and Bb. J Exp Med 1987; 166: 1221–8.
- 43 Medof ME, Walter EI, Rutgers JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med 1987; 165: 848–64.
- 44 Seya T., Turner JR, Atkinson JP. Purification and characterization of a membrane protein (gp45–70) that is a co-factor for cleavage of C3b and C4b. J Exp Med 1986; 163: 837–55.
- 45 Cole J., Houseley GA, Dykman TR, MacDermott RP, Atkinson JP. Identification of an additional class of C3-binding membrane proteins of human peripheral blood leucocytes and cell lines. Proc Natl Acad Sci USA 1985; 83: 8262–63.
- 46 Ross GD, Medof ME. Membrane complement receptors specific for bound fragments of C3. Adv Immunol 1985; 37: 217–67.
- 47 Sim RB, Walport MJ. C3 receptors. In K. Whaley (ed): Complement in Health and Disease. Immunology and Medicine Series. MTP Press Ltd, Lancaster, UK 1987; 125–61.
- 48 Fearon DT. Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated form human erythrocyte membranes. Proc Natl Acad Sci USA 1979; 76: 5867–71.
- 49 Medof ME, Prince GM, Mold C. Release of soluble immune complexes from immune adherence receptors on human erythrocytes is mediated by C3b inactivator independently of β1H and is accompanied by generation of C3c. Proc Natl Acad Sci USA 1982; 79: 5047–51.
- 50 Ross GD, Lambris JD, Cain JA, Newman SL. Generation of three different fragments of bound C3 with purified factor I or serum. I: Requirements for factor H vs CR1 co-factor activity. J Immunol 1982; 129: 2051–60.
- 51 Medicus RG, Melamed J., Arnout MA. Role of human factor I and C3b receptor in the cleavage of surface-bound C3bi molecules. Eur J Immunol 1983; 13: 465–70.
- 52 Fries LF, Siwik SA, Malbran A., Frank MM. Phagocytosis of target particles bearing C3b-IgG covalent complexes by human monocytes and polymorphonuclear leucocytes. Immunology 1987; 62: 45–51.
- 53 Jack RM, Fearon DT. Altered surface distribution of boyh C3b receptors and Fc receptors on neutrophils induced by anti C3b receptor or aggregated IgG. J Immunol 1985; 132: 3028–33.
- 54 Griffin FM. Opsonization, phagocytosis and intracellular microbial killing. In K. Rother, GO Till eds. The complement system. Springer-Verlag, Berlin 1988; 395–418.
- 55 Yamamoto K., Johnston RB jr. Dissociation of phagocytosis from stimulation of the oxidative metabolic burst in macrophages. J Exp Med 1984; 1262: 405–16.
- 56 Iida K., Nadler L., Nussenzweig V. Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med 1983; 158: 1021–33.
- 57 Cooper NR, Moore MD, Nemerow GR. Immunobiology of CR2, the B lymphocyte receptor for Epstein-Barr virus and the C3d complement fragment. Ann Rev Immunol 1988; 6: 85–113.
- 58 Rasmussen JM, Erb K., Rask R., Svehag SE. Complement C3 receptors expressed by human hybridomas. VII International Congress of Immunology, Berlin 1989 (Abstr).
- 59 Tedder TF, Clement LT, Cooper MD. Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB5 monoclonal antibody. J Immunol 1984; 133: 678–83.
- 60 Stashenko P., Nadler LM, Hardy R., Schlossman SF. Expression of cell surface markers after human B lymphocyte activation. Proc Natl Acad Sci USA 1981; 78: 3848–52.
- 61 Micklem KJ, Sim RB, Sim E. Analysis of C3-receptor activity on human B lymphocytes and isolation of complement receptor type 2 (CR2). Biochem J 1984; 224: 75–86.
- 62 Tanner J., Weis J., Fearon DT, Whang Y., Kieff E. Epstein-Barr virus gp 350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping and endocytosis. Cell 1987; 50: 203–13.
- 63 Klaus GGB, Humphrey JH. A re-evaluation of the role of C3 in B-cell activation. Immunology Today 1986; 7: 163–5.
- 64 Klein E., Sarmay G., Ramos OF, Yefenof E., Gergely J. Contribution of activated C3 to lymphocyte mediated cytolysis. Mol Immunol 1986; 26: 1257–62.
- 65 Mold C., Nemerow GR, Bradt BM, Cooper NR. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells. J Immunol 1988; 140: 1923–9.
- 66 Mitomoto K., Fujita T., Iida K. Functional and antigenic properties of complement receptor type 2, CR2. J Exp Med 1987; 165: 1424–9.
- 67 Lachmann PJ, Müller-Eberhard HJ. The demonstration in human serum of conglutinogen activity factor and its effect on the third component of complement. J Immunol 1968; 100: 691–8.
- 68 Ruddy S., Austen KF. C3 inactivator in man. I. Hemolytic measurement by inactivation of cell-bound C3. J Immunol 1969; 102: 533–43.
- 69 Fearon DT. Purification of C3b inactivator and demonstration of its two polypeptide chains. J Immunol 1977; 119: 1248–52.
- 70 Crossley LG, Porter RR. Purification of the human complement control protein C3b inactivator. Biochem J 1980; 191: 173–82.
- 71 Law SK, Fearon DT, Levine RP. Action of the C3b-inactivator on cell bound C3b. J Immunol 1979; 122: 7262–65.
- 72 Davis AE, Harrison RA. Structural characterization of factor I mediated cleavage of the third component of complement. Biochemistry 1982; 21: 574262.
- 73 Seya T., Nagasawa S. Limited proteolysis of complement protein C3b by regulatory enzyme C3b inactivator: Isolation and characterization of a biologically active fragment C3dg. J Biochem 1985; 97: 373–82.
- 74 Malhotra V., Sim RB. Role of complement receptor CR1 in the breakdown of soluble and zymosan-bound C3b. Biochem Soc Trans 1984; 12: 781–2.
- 75 Jepsen HH, Svehag SE, Jensenius JC, Sim RB. Release of immune complexes bound to erythrocyte complement receptor (CR1), with particular reference to the role of factor I. Scand J Immunol 1986; 24: 205–13.
- 76 Lachmann PJ, Pangburn MK, Oldroyd RG. Breakdown of C3 after complement activation. Identification of a new fragment, C3g, using monoclonal antbodies. J Exp Med 1982; 156: 205–16.
- 77 Folkersen J., Teisner B., Eggertsen G., Sim RB. Immunoblotting analysis of the peptide chain structure of the physiological breakdown products of the third component of human complement. Electrophoresis 1986; 7: 379–86.
- 78 Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J Exp Med 1981; 153: 1138–50.
- 79 Podack ER, Müller-Eberhard HJ. Isolation of human S-protein, an inhibitor of the membrane attack complex of complement. J Biol Chem 1979; 254: 9908–14.
- 80 Podack ER, Preissner KT, Müller-Eberhard HJ. Inhibition of C9 polymerization within SC5b-9 complex of complement by S-protein. Acta Path Microbiol Scand Sect C 1984; 92: 89–96.
- 81 Zalman LS, Wood LM, Müller-Eberhard HJ. Isolation of a human erythrocyte membrane protein capable of inhibiting expression of homologus complement transmembrane channels. Proc Natl Acad Sci USA 1986; 83: 697262.
- 82 Schönermark S., Rauterberg EW, Shin ML, Loke S., Roelke D., Hänsch GM. Homologous species restriction in lysis of human erythrocytes: a membrane-derived protein with C8-binding capacity functions as an inhibitor. J Immunol 1986; 136: 1772–6.
- 83 Davies A., Simmons DL, Hale G., Harrison RA, Tighe H., Lachmann PJ, Waldmann H. CD262, an Ly-6-like protein expressed in human lymphoid cells, regulates the action of the complement membrane attack complex on homologus cells. J Exp Med 1989; 170: 637–54.
- 84 Bokisch VA, Müller-Eberhard HJ. Anaphylatoxin inactivator of human plasma: Its isolation and characterization as a carboxypeptidase. J Clin Invest 1970; 49: 2427–36.
- 85 Ross GD, Lambris JD. Identification of a C3bi specific membrane complement receptor that is expressed on lymphocytes, monocytes, neutrophils and erythrocytes. J Exp Med 1982; 155: 96–110.
- 86 Ross GD, Cain JA, Lachmann PJ. Membrane complement receptor type 3 (CR3) has lectin-like properties analogous to bovine conglutinin and functions as a receptor for zymosan and rabbit erythrocytes as well as a receptor for iC3b. J Immunol 1985; 134: 3307–15.
- 87 Ross GD, Cain JA, Myones BL, Newman SL, Lachmann PJ. Specificity of membrane complement receptor type 3 (CR3) for β-glucans. Complement 1987; 4: 61–74.
- 88 Cain JA, Newman SL, Ross GD. Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement 1987; 4: 75–86.
- 89 Ramos OF, Kai C., Yefenof E., Klein E. The elevated natural killer sensitivity of targets carrying surface-attached C3 fragments require the avaiability of the iC3b receptor (CR3) on the effectors. J Immunol 1988; 140: 1239–43.
- 90 Frade R., Myones BL, Barel M., Krikorian L., Charriaut C., Ross GD. gpl40, a C3b-binding membrane component of lymphocytes, is the B cell C3dg/C3d receptor (CR2) and is distinct from the neutrophil C3dg receptor (CR4). Eur J Immunol 1985; 15: 1192–7.
- 91 Vik DP, Fearon DT. Neutrophils express a receptor for iC3b, C3dg and C3d that is distinct from CR1, CR2 and CR3. J Immunol 1985; 134: 2571–9.
- 92 Vik DP, Fearon DT. Cellular distribution of complement receptor type 4 (CR4): expression on human platelets. J Immunol 1987; 138: 254–8.
- 93 Micklem KJ, Sim RB. Isolation of complement-fragment-iC3b-binding proteins by affinity chromatography. The identifiction of pl50,95 as an iC3b-binding protein. Biochem J 1985; 231: 233–6.
- 94 Bitter-Suermann D. The anaphylatoxins. In K. Rother, GO Till eds. The complement system. Springer-Verlag, Berlin 1988; 367–95.
- 95 Morgan EL. Modulation of the immune response by anaphylatoxins. Complement 1986; 3: 128–36.
- 96 Miller GW, Nussenzweig V. A new complement function: Solubilization of antigen-antibody aggregates. Proc Natl Acad Sci USA 1975; 72: 418–22.
- 97 Baatrup G. Immune complex modulation by plasma proteins, with special reference to the complement system and autoimmune diseases ( Thesis). Dan med Bull 1989; 36; 443–63.
- 98 Petersen I., Baatrup G., Jepsen HH, Svehag SE. Complement-mediated solubilization of immune complexes and their interaction with complement C3 receptors. Complement 1985; 2: 97–110.
- 99 Fujita T., Takata Y., Tamura N. Solubilization of immune preci-pitates by six isolated alternative pathway proteins. J Exp Med 1981; 154: 1743–51.
- 100 Takahashi M., Tack BF, Nussenzweig V. Requirements for the solubilization of immune aggregates by complement. J Exp Med 1977; 145: 86–99.
- 101 Nydegger UE, Corvetta A., Spaeth PJ, Spycher M. The alternative complement pathway control protein H binds to immune complexes and serves their detection. Clin Immunol Immunopathol 1983; 26: 56–65.
- 102 Takahashi M., Takahashi S., Brade V., Nussenzweig V. Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest 1978; 62: 349–58.
- 103 Schifferly JA, Bartolotti R., Peters DK. Inhibition of immune precipitation by complement. Clin Exp Immunol 1980; 42: 387–94.
- 104 Schifferly JA, Steiger G., Hauptmann G., Spaeth PJ, Sjöholm AG. Formation of soluble immune complexes by complement in sera of patients with various hypocomple-mentemic states. Difference between inhibition of immune precipitation and solubilization. J Clin Invest 1985; 76: 2127–33.
- 105 Hebert LA, Cosio FG. The erythrocyte-immune complex-glomerulonephritis connection in man. Kidney Int 1987; 31: 877–85.
- 106 Schifferly JA, Ng YC, Peters DK. The role of complement and its receptors in the elimination of immune complexes. N Engl J Med 1986; 315: 488–95.
- 107 Medof ME, Oger JJF. Competition for immune complexes by red cells in human blood. J Clin Lab Immunol 1982; 7: 7–13.
- 108 Medof ME, Prince GM, Oger JJF. Kinetics of interaction of immune complexes with complement receptors on human blood cells: Modification of complexes during interaction with red cells. Clin Exp Immunol 1982; 48: 715–25.
- 109 Jepsen HH, Svehag SE, Jarlbæk L., Baatrup G. Interaction of complement-solubilized immune complexes with CR1-receptors on human erythrocytes. The binding reaction. Scand J Immunol 1986; 23: 65–73.
- 110 Horgan C., Burge J., Crawford L., Taylor RP. The kinetics of [3H]-dsDNA/antiDNA immune complex formation, binding by red blood cells and release into serum: Effect of DNA molecular weight and conditions of antibody excess. J Immunol 1984; 133: 2079–84.
- 111 Medof ME, Lam T., Prince GM, Mold C. Requirement for human red blood cells in inactivation of C3b in immune complexes and enhancement of binding to spleen cells. J Immunol 1983; 130: 1336–40.
- 112 Rask R., Rasmussen JM, Jepsen HH, Svehag SE. Enhanced binding of immune complexes processed by eythrocyte CR1 (CD35) receptors to purified CR2 (CD21) from tonsillar mononuclear cells. Acta Path Microbiol Scand Sect C 1989; 97: 374–80.
- 113 Medof ME, Prince GM. Immune complex alterations occur on the human red blood cell membrane. Immunology 1983; 50: 11–8.
- 114 Cornacoff JB, Hebert LA, Smead WL, Van Aman ME, Birmingham DJ, Wazman FJ. Primate erythrocyte-immune complex-clearing mechanism. J Clin Invest 1983; 71: 236–47.
- 115 Waxman FJ, Hebert LA, Cornacoff JB, Van Aman ME, Smead WL, Kraut EH, Birmingham DJ, Taguiam JM. Complement depletion accelerates the clearance of immune complexes form the circulation of primates. J Clin Invest 1984; 74: 1329–40.
- 116 Schifferli JA, Ng YC, Estreicher J., Walport MJ. The clearance of tetanus toxoid/anti-tetanus toxoid immune complexes from the circulation of humans. Complement- and erythrocyte complement receptor 1-dependent mechanisms. J Immunol 1988; 140: 899–904.
- 117 Hauptmann G. Frequency of complement deficiencies in man, disease associations and chromosome assignment of complement genes and linkage groups. Complement Inflamma 1989; 6: 74–80.
- 118 Silverstein AM. Essential hypocomplementemia. Report of a case. Blood 1960; 16: 1338–1341.
- 119 Rynes RI. Inherited complement deficiency states and SLE. Clin Rheum Dis 1982; 8: 29–47.
- 120 Lachmann PJ, Walport MJ. Genetic deficiency diseases of the complement system. In GD Ross (ed): Immunobiology of the complement system. Academic Press Inc, New York 1986, 237–61.
- 121 K. Rother, U. Rother (eds): Hereditary and Acquired complement deficiencies in animals and man. Progress in Allergy vol. 39, Karger 1986.
- 122 Hauptmann G., Tappeiner G., Schifferli JA. Inherited deficiency of the fourth component of human complement. Immunodef Rev 1988; 1: 3–22.
- 123 Alper CA, Awdeh ZL, Yunis EJ. Complotypes and extended haplotypes in laboratory medicine. Complement 1989; 6: 8–18.
- 124 Schifferli JA, Hauptmann G., Paccaud JP. Complement-mediated adherence of immune complexes to human erythrocytes. Difference in requirements for C4A and C4B. FEBS Letters 1987; 213: 415–8.
- 125 Atkinson JP, Chan AC, Karp DR, Killion CC, Brown R., Spinella D., Schreffler DC, Levine RP. Origin of the fourth component of complement related Chido and Rodgers blood group antigens. Complement 1988; 5: 65–76.
- 126 Rynes RI, Britten AFH, Pickering RJ. Deficiency of the second complement component: Association with the HLA haplotype A10, B18 in a normal population. Ann Rheum Dis 1982; 41: 93–6.
- 127 Provost TT, Arnett FC, Reichlin M. Homozygous C2 deficiency, lupus erythematosus and anti Ro (SSA) antibodies. Arthritis Rheum 1983; 26: 1279–82.
- 128 Meyer O., Hauptmann G., Tappeiner G., Ochs HD, Mascart-Lemone F. Genetic deficiency of C2, C4 or C1q and lupus syndromes. Association with anti-Ro (SS-A) antibodies. Clin Exp Immunol 1985; 62: 678–84.
- 129 Alper CA, Collen HR, Rosen FS, Rabson AR, MacNab GM, Geer JSS. Homozygous deficiency of C3 in a patient with repeated infections. Lancet 1972; ii: 1179–81.
- 130 Ballow M., Shira JE, Harden L., Yang SY, Day NK Complete absence of the third component of complement in man. J Clin Invest 1975; 56: 703–10.
- 131 Grace HJ, Brereton-Stiles GG, Vos GH, Schonland M. A family with partial and total deficiency of complement C3. S Afr Med J 1976; 50: 139–40.
- 132 Davis AE, Davis JS, Rabson AR, Osofsky SG, Colten HR, Rosen FS, Alper CA. Homozygous C3 deficiency: Detection of C3 by radio-immunoassay. Clin Immunol Immunopathol 1977; 8: 543–50.
- 133 Hsieh KH, Lin CY, Lee TC. Complete absence of the third component of complement in a patient with repeated infections. Clin Immunol Immunopathol 1981; 20: 305–12.
- 134 Roord JJ, Daha M., Kuis W., Verbrugh HA, Verhoef J., Zegers BJM, Stoop JW. Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes and vasculitis in a Dutch family. Pediatrics 1983; 71: 81–7.
- 135 Osofsky SG, Thompson BH, Lint TF, Gewurz H. Hereditary deficiency of the third component of complement in a child with fever, skin rash and arthralgias. J Pediatr 1977; 90: 180–6.
- 136 Sano Y., Nishimukai H., Kitamura H., Nagaki K., Inai S., Hamasaki Y., Maruyama I., Igata A. Hereditary deficiency of the third component of complement in two sisters with systemic lupus erythematosus-like symptoms. Arthr Rheum 1981; 24: 1255–60.
- 137 Newman SL, Vogler LB, Feigin RD, Johnston RB. Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. N Engl J Med 1978; 299: 290–2.
- 138 Mauff G., Federmann G., Hauptmann G. A hemolytically inactive gene product of factor B. Immunobiol 1980; 158: 96–100.
- 139 Kluin-Nelemans HC, Velzen-Blad Hv, Helden HPTv, Daha MR. Functional deficiency of complement factor D in a monozygous twin. Clin Exp Immunol 1984; 58: 724–30.
- 140 Petersen BH, Lee TJ, Snyderman R., Brooks GF. Neisseria meningitidis and Neisseria gonorrhoeae bacteremia associated with C6, C7 or C8 deficiency. Ann Int Med 1979; 90: 917–20.
- 141 Trapp RG, Mooney E., Coleman TH, Forristal J., Herman JH. Hereditary complement (C6) deficiency associated with systemic lupus erythematosus, Sjögrens syndrome and hyperthyroidism. J Rheumatol 1987; 14: 1030–3.
- 142 Reinitz E., Lawrence M., Diamond B., Keiser H., Alper C. Arthritis and antinuclear antibodies with inherited deficiency of the sixth component of complement. Ann Rheum Dis 1986; 45: 431–4.
- 143 Tedesco F. Component deficiencies: The eighth component. In K. Rother, U. Rother (eds): Hereditary and Acquired complement deficiencies in animals and man. Progress in Allergy, Karger 1986; 39: 295–306.
- 144 Lachmann PJ, Hobart MJ, Woo P. Combined genetic deficiency of C6 and C7 in man. Clin Exp Immunol 1978; 33: 193–203.
- 145 Morgan BP, Vora JP, Bennett AJ, Thomas JP, Matthews N. A case of hereditary combined deficiency of complement components C6 and C7 in man. Clin Exp Immunol 1989; 75: 396–401.
- 146 Späth PJ, Zoppi M., Weiss T., Meyer-Hänni L., Nydegger UE, Molines TE. Recurrent meningitis. The first case of C9 deficiency in Europe. Complement 1988; 5: 182 (abstr).
- 147 Inai S., Kitamura H., Hiramatsu S., Nagaki K. Deficiency of the ninth component of complement in man. J Clin Lab Immunol 1979; 2: 85–7.
- 148 Nagata M., Hara T., Aoki T., Mizuno Y., Akeda H., Inaba S. Inherited deficiency of ninth component of complement: An increased risk of meningoccocal meningitis. J Pediatr 1989; 114: 260–4.
- 149 Inai S., Moriyama T. The suceptibility of C9-deficient individuals to meningococcal infection. VII International Congress of Immunology, Berlin, 1989 (Abstr).
- 150 Agostini A. Inherited C1 inhibitor deficiency. Complement 1989; 6: 112–8.
- 151
Donaldson VH.
Hereditary angioneurotic edema.
Dis Month
1979; 26: 8–35.
10.1016/S0011-5029(79)80015-2 Google Scholar
- 152 Massa MC, Conolly MD. An association between C1-esterase inhibitor deficiency and lupus erythematosus. Report of two cases and review of the literature. J Am Acad Dermatol 1982; 7: 255–64.
- 153 Davis CA, Forristal J. Partial properdin deficiency. J Lab Clin Med 1980; 96: 633–9.
- 154 Sjöholm AG, Braconier JH, Söderström C. Properdin deficiency in a family with fulminant meningococcal infections. Clin Exp Immunol 1982; 52: 291–7.
- 155 Braconier JH, Sjöholm A., Söderström C. Fulminant meningococcal infections in a family with inherited deficiency of properdin. Scand J Infect Dis 1983; 15: 339–45.
- 156 Densen P., Weiler JM, Griffiss JM, Hoffmann LG. Familial properdin deficiency and fatal meningococcemia. Correction of the bactericidal defect by vaccination. N Engl J Med 1987; 316: 922–6.
- 157 Nielsen HE, Koch C. Congenital properdin deficiency and meningococcal infection. Clin Immunol Immunopathol 1987; 316: 134–9.
- 158 Wyatt RJ, Julian BA, Galla JH. Properdin deficiency with IgA nephropathy. New Engl J Med 1981; 305: 1097.
- 159 Ruddy S., Purkall DB, Gelfand EW. Formation of unstable alternative pathway convertase in properdin deficient serum. Complement 1985; 2: 68 (abstr).
- 160 Söderström C., Braconier JH, Käyhty S., Sjöholm AG, Thuresson B. Immune response to tetravalent meningococcal vaccine: opsonic and bactericidal functions of normal and properdin deficient sera. Eur J Clin Microbiol Infect Dis 1989; 8: 220–4.
- 161 Sjöholm AG, Kuijper EJ, Tijssen CC, Jansz A., Bol P., Spanjaard L., Zanen HC. Dysfunctional properdin in a Dutch family with meningococcal disease. N Engl J Med 1988; 319: 33–7.
- 162 Nielsen HE, Koch C., Magnussen P., Lind I. Complement deficiencies in selected groups of patients with meningoccoccal disease. Scand J Infect Dis 1989; 21: 389–96.
- 163
Fijen CAP,
Kuijper EJ,
Hannema AJ,
Sjöholm AG,
Van Putten JPM.
Complement deficiencies in patients over ten years old with meningococcal disease due to uncommon serogroups.
Lancet
1989; ii: 585–8.
10.1016/S0140-6736(89)90712-5 Google Scholar
- 164 Thompson RA, Winterborn MH. Hypocomplementemia due to genetic deficiency of β1H globulin. Clin Exp Immunol 1981; 46: 110–9.
- 165
Lopez-Larrea C.,
Dieguez MA,
Enguix A.,
Dominiguez O.,
Marin B.,
Gomez E.
A familial deficiency of complement factor H.
Biochem Soc Trans
1987; 15: 648–9.
10.1042/bst0150648 Google Scholar
- 166 Wyatt RJ, Julian BA, Weinstein A., Rothfield NF, McLean RH. Partial H (β1H) deficiency and glomerulonephritis in two families. J Clin Immunol 1982; 2: 110–7.
- 167 Levy M., Halbwachs-Mecarelli L., Gubler MC, Kohout G., Bensenouci A., Niaudet P., Hauptmann G., Lesavre P. H deficiency in two brothers with atypical dense intramembranous deposit disease. Kidney Int 1986; 30: 949–56.
- 168 Brai M., Misiano G., Maringhini S., Cutaja I., Hauptmann G. Combined homozygous factor H and heterozygous C2 deficiency in an italian family. J Clin Immunol 1988; 8: 50–6.
- 169 Nielsen HE, Christensen KC, Koch C., Thomsen BS, Heegaard NHH, Tranum-Jensen J. Hereditary, complete deficiency of complement factor H associated with recurrent meningoccoccal disease. Scand J Immunol 1989; 30: 711–8.
- 170 Wilson JG, Wong WW, Schur P., Fearon DT. Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med 1982; 307: 981–6.
- 171 Walport MJ, Ross GD, Mackworth-Young C., Watson JV, Hogg N., Lachmann PJ. Family studies of complement receptor type 1 levels: reduced levels in patients with SLE are required, not inherited. Clin Exp Immunol 1985; 262: 547–54.
- 172 Holme E., Fyfe A., Zoma A., Veitch J., Hunter J., Whaley K. Decresed C3b receptors (CR1) on erythrocytes from patients with SLE. Clin Exp Immunol 1985; 62: 261–8.
- 173 Thomsen BS. Human erythrocyte complement receptor type 1 (CRT): Expression, function and role in the pathogenesis of inflammatory connective tissue diseases ( Thesis). Dan Med Bull 1988; 35: 414–22.
- 174 Miyakawa Y., Yamada A., Kosaka K., Tsuda F., Kosugi E., Mayumi M. Defective immune adherence receptor (C3b) on erythrocytes from patients with systemic lupus erythematosus. Lancet 1981; ii: 493–7.
- 175 Iida K., Mornaghi R., Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. N Engl J Med 1982; 155: 1427–38.
- 176 Ross GD, Yount WJ, Walport MJ, Winfield JB, Parker CJ, Fuller C., Taylor RP, Myones BL, Lachmann PJ. Disease-associated loss of erythrocyte complement receptors in patients with systemic lupus erythematosus and other diseases involving autoantibodies and/or complement activation. J Immunol 1985; 135: 2005–14.
- 177 Jepsen HH, Rasmussen JM, Teisner B., Nielsen UH, Jarlbæk L., Isager H., Svehag SE. Immune complex binding to erythrocyte CR1 (CD-35), CR1-expression and levels of erythrocyte-fixed C3d and plasma C3d in patients with systemic lupus erythematosus. APMIS, in press.
- 178 Porteu F., Fischer A., Descamps-Latscha B., Halbwachs-Mecarelli L. Defective complement receptors (CR1 and CR3) on erythrocytes and leukocytes of factor I (C3b-in-activator) deficient patients. Clin Exp Immunol 1986; 66: 463–71.
- 179 Jepsen HH, Teisner B., Rasmussen JM, Svehag SE. Reduced erythrocyte CR1 (CD35) receptor function and complement opsonization in factor I deficient patients is restored by plasma infusion. Scand J Immunol 1989; 29: 247–55.
- 180 Walport M., Ng YC, Lachmann PJ. Erythrocytes transfused into patients with SLE and hemolytic anemias lose complement receptor type 1 from their cell surface. Clin Exp Immunol 1987; 69: 501–7.
- 181 Walport MJ, Lachmann PJ. Erythrocyte complement receptor type 1, immune complexes and the rheumatic diseases. Arthr Rheum 1988; 31: 153–8.
- 182 Schwaber JF, Klein G., Ernberg I., Rosen A., Lazarus H., Rosen FS. Deficiency of Epstein-Barr virus (EBV) receptors on B lymphocytes from certain patients with common varied agammaglobulinemia. J Immunol 1980; 124: 2191–6.
- 183 Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum 1986; 29: 739–47.
- 184 Rask R., Rasmussen JM, Teisner B., Jepsen H., Svehag SE. Complement C3dg/Epstein Barr virus receptor density on human B-lymphocytes is elevated in patients with systemic lupus erythematosus. Complement Inflamm 1989; 6: 391 (abstr).
- 185 Ross GD. Clinical and laboratory features of patients with an inherited deficiency of neutrophil membrane complement receptor type 3 (CR3) and the related membrane antigens LFA-1 and p150,95. J Clin Immunol 1986; 6: 107–13.
- 186 Springer TA, Anderson DC. The importance of the Mac-1, LFA-1 glycoprotein family in monocyte and granulocyte adherence, Chemotaxis and migration into inflammatory sites: insights from an experiment of nature. In Biochemistry of macrophages. Ciba Foundation Symposium no 118, Pitman, London 1986: 102–26.
- 187 Halperin JA, Nicholson-Weller A. Paroxysmal nocturnal hemoglobinuria. A complement-mediated disease. Complement Inflamm 1989; 6: 65–72.
- 188 Zalman LS, Wood LM, Frank MM, Müller-Eberhard HJ. Deficiency of the homologous restriction factor in paroxysmal nocturnal hemoglobinuria. J Exp Med 1987; 165: 572–7.
- 189 Spitzer RE, Vallota EH, Forristal J., Sudora E., Stitzel A., Davis NC, West CD. Serum C'3 lytic system in patients with glomerulonephritis. Science 1969; 164; 436–7.
- 190 Sissons JGP, West RJ, Fallows J., Williams DG, Boucher BJ, Amos N., Peters DK. The complement abnormalities of lipodystrophy. N Engl J Med 1976; 294: 461–5.
- 191 Alper CA, Bloch KJ, Rosen FS. Increased susceptibility to infection in a patient with type II essential hypercatabolism of C3. N Engl J Med 1973; 288: 601–6.
- 192 Böhles H., Kövary PM. Partielle lipodystrophie mit osteomyelitis. Klin Pädiat 1982; 194: 124–7.
- 193 Edwards KM, Alford R., Gewurz H., Mold C. Recurrent bacterial infections associated with C3 Nephritic factor and hypocomplementemia. N Engl J Med 1983; 308: 1138–41.
- 194 Thompson RA, Yap PL, Brettle RB, Dunmow RE, Chapel H. Meningococcal meningitis associated with persistent hypocomplementemia due to circulating nephritic factor. Clin Exp Immunol 1983; 52: 153–6.
- 195 Teisner B., Elling P., Svehag SE, Poulsen L., Lamm LU, Sjöholm AG. C3 nephritic factor in a patient with recurrent Neisseria meningitidis infections. Acta Path Microbiol Scand Sect C 1984; 92: 341–9.
- 196
Karstorp A.
C3 activator and hypocomplementaemia in a “healthy” woman.
Brit Med J
1976; i: 501–2.
10.1136/bmj.1.6008.501-a Google Scholar
- 197 Gewurz AT, Imherr SM, Strauss S., Gewurz H. C3 nephritic factor and hypocomplementemia in a clinically healthy individual. Clin Exp Immunol 1983; 54: 253–8.
- 198 Lopez-Trascasa M., Vicario JL, Martin JM, Marin MA, Martinez-Ara J., Garcia-Messeguer MC, Arnaiz A., Fontán G. Familiar incidence of C3 nephritic factor. Complement 1986; 3: 16 (abstr).
- 199 Davis AE, Arnout MA, Alper CA, Rosen FS. Transfer of C3 Nephritic factor from mother to fetus. Is C3 Nephritic factor IgG N Engl J Med 1977; 297: 144–5.
- 200 Scott DM, Amos N., Sissons JGP, Lachmann PJ, Peters DK. The immunoglobulin nature of nephritic factor (NeF). Clin Exp Immunol 1978; 32: 12–24.
- 201 Daha MR, Van Es LA. Further evidence for the antibody nature of C3 nephritic factor (C3Nef). J Immunol 1979; 123: 755–8.
- 202 Daha MR, Fearon DT, Austen KF. C3 nephritic factor (C3NeF): Stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol 1976; 116: 1–7.
- 203 Daha, M.R., Austen, K.F. and Fearon, D.T. The incorporation of C3 nephritic factor (C3NeF) into a stabilized C3 convertase, C3bBb(C3NeF), and its release after decay of convertase function. J Immunol 1977; 119: 812–7.
- 204 Mold, C. and Medof, M.E. C3 nephritic factor protects bound C3bBb from cleavage by factor I and human erythrocytes. Mol. Immunol. 1985; 22: 507–12.
- 205 Daha MR, Van Es LA. Stabilization of homologous and heterologous cellbound amplification convertases, C3bBb, by C3 nephritic factor. Immunology 1984; 43: 33–8.
- 206 Daha MR, Deelder AM, Van Es LA. Stabilization of the amplification convertase of complement by monoconal antibodies directed agianst human factor B. J Immunol 1984; 132: 2538–42.
- 207 Halbwachs L., Leveillè M., Lesavre PH, Wattel S., Leibowitch J. Nephritic factor of the classical pathway. Immunoglobulin G autoantibody directed against the classical pathway C3 convertase enzyme. J Clin Invest 1980; 65: 1249–56.
- 208 Fujita T., Sumita T., Yoshida S., Ito S., Tamura N. C4 nephritic factor in patients with chronic glomerulonephritis. J Clin Lab Immunol 1987; 22: 65–70.
- 209 Jackson J., Sim RB, Whelan A., Feighery C. An IgG autoantibody which inactivates C1-inhibitor. Nature 1986; 323: 722–4.
- 210 Hässig A., Borel JF, Ammann P., Thoni M., Butler R. Essentielle hypokomplementämie. Pathol Microbiol 1964; 27: 542–7.
- 211 Torisu M., Arata M., Sonozaki H., Majima H. C'3c deficient human sera with a β1c precipitin line. J Immunol 1967; 99: 629–39.
- 212 Torisu M., Sonozaki H., Inai S., Arata M. Deficiency of the fourth component of complement in man. J Immunol 1970; 104: 728–37.
- 213 Lachmann PJ. Genetic deficiencies of the complement system. Bull 1st Sieroter Milan 1974; 53: 195–207.
- 214 Glass D., Raum D., Gibson D., Stillman JS, Schur PH. Inherited deficiency of the second component of complement: Rheumatic disease associations. J Clin Invest 1976; 58: 853–61.
- 215 Alper CA, Awdeh Z., Yunis EJ. Frequency of the C2 deficiency gene among normal Caucasians. Complement 1987; 4: 125 (abstr).
- 216 Inaba S., Okochi K., Fukuda K., Kinoshita S., Maeda Y., Yoshinari M. The occurence of precipitating antibodies in transfused japanese patients with hereditary ninth component of complement deficiency and frequency of C9 deficiency. Transfusion 1987; 27: 475–7.
- 217 Lee TJ, Schmoyer A., Snyderman R., Yount WJ, Sparling PF. Familial deficiencies of the sixth and seventh components of complement associated with bacteremic Neisseria infections. In GF Brooks, EC Gotschlich, KK Holmes, WD Sawyer, FE Young (eds): Immunobiology of Neisserial gonorrhea. American Society for Microbiology, Washington DC 1978; 204–6.
- 218 Eng RHK. Bactericidal screening test for late complement component deficiencies or defects. J Clin Microbiol 1980; 11: 631–4.
- 219 Zimran A., Rudensky B., Kramer MR, Tedesco F., Ehrenfeld M., Raz R., Greif Z., Gelber M., Lishner M., Golan E., Hershko C. Hereditary complement deficiency in survivors of meningococcal disease: High prevalence of C7/C8 deficiency in Sephardic (Moroccan) jews. Q J Med 1987; 63: 349–58.
- 220 Beatty DW, Ryder CR, Heese, Hdv. Complement abnormalities during an epidemic of group B meningococcal infection in children. Clin Exp Immunol 1986; 64: 465–70.
- 221 Coleman TH, Forristal, J., Kosaka T., West CD. Inherited complement component deficiencies in membranoproliferative glomerulo-nephritis. Kidney Int 1983; 24: 681–90.
- 222 Weihe P., Matthiassen B., Rasmussen JM, Petersen T., Isager H. An epidemic outbreak of meningococcal disease on the Faroe Islands. Scand J Infect Dis 1988; 20: 291–6.
- 223 Lind I., Joensen HD, Poolman JT, Zoffman H. Meningococcal disease in the Faroe Islands. Antonie van Leuwenhook J Microbiol 1986; 52: 223–4.
- 224 Orren A., Potter PC, Cooper RC, du Toit E. Deficiency of the sixth component of complement and susceptibility to Neisseria meningitidis infections: Studies in 10 families and five isolated cases. Immunology 1987; 62: 249–53.
- 225 Geiseler PJ, Nelson KE, Levin S., Reddi KT, Moses VK. Community acquired purulent meningitis. A review of 1316 cases during the antibiotic era 1954–1976. Rev Infect Dis 1980; 2: 725–45.
- 226 Bohr V., Hansen B., Jessen O., Johnsen N., Kjersem H., Kristensen HS, Nyboe J., Rasmussen N. Eight hundred and seventy five cases of bacterial meningitis: Clinical data, prognosis, and the role of specialized hospital departments. J Infect 1983; 7: 21–30.
- 227 Mayer MM. Complement and complement fixation. In: EA Kabat, MM Mayer eds. Experimental Immunochemistry. Charles C Thomas, Springfield, Ill, USA 1961: 133–240.
- 228 Platts-Mills TAE, Ishizaka K. Activation of the alternative pathway of human complement by rabbit cells. J Immunol 1974; 113: 348–58.
- 229 Teisner B., Brandslund I., Folkersen J., Rasmussen JM, Poulsen LO, Svehag SE. Factor I deficiency and C3 Nephritic factor: Immunochemical findings and association with Neisseria meningitidis infection in two patients. Scand J Immunol 1984; 20: 291–7.
- 230 Nilsson UR, Nilsson B. Simplified assays of hemolytic activity of the classical and alternative complement pathways. J Immunol Methods 1984; 72: 49–262.
- 231 Truedson L., Sjöholm AG, Laureil AB. Screening for deficiencies in the classical and alternative pathways of complement by hemolysis in gel. Acta Path Microbiol Scand Sect C 1981; 89: 161–6.
- 232 Gewurz AT, Lint TF, Imherr SM, Garber SS, Gewurz H. Detection and analysis of inborn and acquired complement abnormalities. Clin Immunol Immunopathol 1982; 23: 297–311.
- 233 Polhill RB Jr., Pruitt KM, Johnston RB. Jr. Kinetic assessment of alternative complement pathway activity in a hemolytic system. I: Experimental and mathematical analyses. J Immunol 1978; 121: 363–70.
- 234
Boackle RJ,
Pruitt KM.
A convenient method for the study of anticomplementary substances in biologogical fluids. In: H. Peeters ed.
Protides of the Biological Fluids. Oxford, Pergamon Press, 1974; vol 21: 613–7.
10.1016/B978-0-08-017822-6.50103-9 Google Scholar
- 235 Alper CA, Abramson N., Johnston RB, Jandl JH, Rosen FS. Increased susceptibility to infection associated with abnormalities of complement-mediated functions and of the third component of complement (C3). N Engl J Med 1970; 282: 349–52.
- 236 Alper CA, Abramson N., Johnston RB, Jandl JH, Rosen FS, Watson L. Studies in vivo and in vitro on an abnormality in the metabolism of C3 in a patient with increased susceptibility to infection. J Clin Invest 1970; 49: 1975–85.
- 237 Alper CA, Rosen FS, Lachmann PJ. Inactivator of the third component of complement as an inhibitor in the properdin pathway. Proc Natl Acad Sci 1972; 69: 2910–13.
- 238 Abramson N., Alper CA, Lachmann PJ, Rosen FS, Jandl JH. Deficiency of C3b inactivator in man. J Immunol 1971; 107: 19–27.
- 239 Thompson RA, Lachman PJ. A second case of human C3b inhibitor (KAF) deficiency. Clin Exp Immunol 1977; 27: 23–9.
- 240 Eng RHK, Seligman SJ, Arnout MA, Alper CA. Variable expression of homozygous C3b inactivator deficiency. Clin Res 1978; 26: 394 (abstr).
- 241 Wahn V., Rother U., Rauterberg EW, Day NK, Laurell B. C3b inactivator deficiency: Association with an α-migrating factor H. J Clin Immunol 1981; 1: 228–33.
- 242 Barrett DJ, Boyle MDP. Restoration of complement function in vivo by plasma infusion in factor I (C3b inactivator) deficiency. J Pediatr 1984; 104: 76–81.
- 243 Solal-Celigny P., Laviolette M., Herbert J., Atkins PC, Siriois M., Brun G., Lehner-Netsch G., Delage JM. C3b-inactivator deficiency with immune-complex manifestations. Clin Exp Immunol 1982; 47: 197–205.
- 244 Morris KM, Aden DP, Knowles B., Colten HR. Complement biosynthesis by the human hepatoma derived cell line HepG2. J Clin Invest 1982; 70: 906–13.
- 245 Whaley K. Biosynthesis of of the complement component and regulatory proteins of the alternative pathway by human peripheral blood monocytes, J Exp Med 1980; 151: 501–16.
- 246 Goldberger G., Bruns GAP, Rits M., Edge MD, Kwiatkowski DJ. Human complement factor I: Analysis of cDNA-derived primary structure. Biochemistry 1987; 262: 10065–71.
- 247 Köble K., Buckle V., Lefranc G., Halbwachs Mecarelli, Møller-Rasmussen J., Sim RB, Späth P., Svehag SE, Teisner B., Wahn V. Physical mapping of the complement factor I gene in normal and deficient genomes. Complement Inflamm 1989; 6: 355 (abstr).
- 248 Nishimukai H., Tamaki Y. I typing by agarose gel isoelectric focusing. Human Hered 1986; 36: 195–7.
- 249 Yuasa I., Umetsu K., Suenaga K., Ito K., Iha M., Hirata H., Robinet-levy M., Inoue T., Okada K. Factor I (C3b inactivator) polymorfism among five populations in Eurasia. Human Hered 1988; 38: 91–4.
- 250
Zhou M.,
Larsen B.
A new polymorphic variant of human complement factor I.
Hum Gen
1989; 82: 293.
10.1007/BF00274006 Google Scholar
- 251 Ziegler JB, Rosen FS, Alper CA, Grupe W., Lepow IH. Metabolism of properdin in normal subjects and patients with renal disease. J Clin Invest 1975; 56: 761–7.
- 252 Ziegler JB, Alper CA, Rosen FS, Lachmann PJ, Sherington L. Restoration by purified C3b inactivator of complement-mediated function in vivo in a patients with C3b inactivator deficiency. J Clin Invest 1975; 55: 668–72.
- 253 Baatrup G., Petersen I., Svehag SE, Jepsen HH, Brandslund I. Solubilization of immune complexes in complement factor deficient sera and the influence of temperature, ionic strength and divalent cations on the solubilization reaction. J Clin Lab Immunol 1984; 14: 185–9.
- 254 Nicol PAE, Lachmann PJ. The alternate pathway of complement activation. The role of C3 and its inactivator (KAF). Immunology 1973; 24: 2262–75.
- 255 Charlesworth JA, Gwyn-Williams D., Sherington E., Lachmann PJ, Peters DK. Metabolic studies of the third component of complement and the glycine-rich β-glycoprotein in patients with hypocomplementemia. J Clin Invest 1974; 53: 1578–87.
- 256 Perlmutter DH, Colten HR. Molecular immunobiology of complement biosynthesis: A model of single-cell control of effector-inhibitor balance. Ann Rev Immunol 1986; 4: 231–51.
- 257 Steinsson K., Erlendsson K., Valdimarsson H. Succesful plasma infusion treatment of a patient with C2 deficiency and systemic lupus erythematosus: clinical experience over forty-five months. Arthritis Rheum 1989; 32: 906–13.
- 258 Dukor P., Hartmann KU. Bound C3 as the scond signal for B cell activation. Cell Immunol 1973; 7: 349–55.
- 259 Pepys MB. Role of complement in the induction of immunological responses. Transplant Rev 1976; 32: 93–120.
- 260 Klaus GGB. Role of complement in the induction of antibody responses. In K. Rother, GO Till eds. The complement system. Springer-Verlag, Berlin 1988; 328–37.
- 261 Klaus GGB, Humphrey JH. The generation of memory cells. I. The role of C3 in the generation of memory B cells. Immunology 1977; 33: 31–40.
- 262 Mandel TE, Phipps RP, Abbot A., Tew JG. The follicular dendritic cell: long-term antigen retention during immunity. Immunol Rev 1980; 53: 29–262.
- 263 Reynes M., Aubert JP, Cohen JHM, Audoin J., Tricollet V., Diebold J., Kazatchkine MD. Human follicular cells express CR1, CR2 and CR3 complement receptor antigens. J Immunol 1985; 135: 2687–94.
- 264 Papamichail M., Gutierrez C., Embling P., Johnson P., Holborow EJ. Complement dependency of localization of aggregated IgG in germinal centers. Scand J Immunol 1975; 4: 343–350.
- 265 Heyman B., Andrighetto G., Wigzell H. Antigen dependent IgM-mediated enhancement of the sheep erythrocyte response in mice. Evidence for induction of B cells with specificities other than that of the injected antigen. J Exp Med 1982; 155: 994–1009.
- 266 Heyman B., Pilström L., Shulman MJ. Complement activation is required for IgM-mediated enhancement of the antibody response. J Exp Med 1988; 167: 1999–2004.
- 267 Erdei A., Melchers F., Schulz T., Dierich MP. The action of human C3 in soluble or cross-linked form with resting and activated murine B lymphocytes. Eur J Immunol 1985; 15: 184–8.
- 268 Melchers F., Erdei A., Schulz T., Dierich MP. Growth control of activated, synchronized murine B cells by the C3d-fragment of human complement. Nature 1985; 317: 264–7.
- 269 Melchers F., Erdei A., Corbel C., Leptin M., Schulz T., Dierich MP. Cell cycle control of activated synchronized murine B lymphocytes - roles of macrophages and complement. Mol Immunol 1986; 23: 1173–6.
- 270 Frade R., Crevon MC, Barel M. et al. Enhancement of human B cell proliferation by an antibody to the C3d receptor, the gpl40 molecule. Eur J Immunol 1985; 15: 73–6.
- 271 Nemerow GR, McNaughton ME, Cooper NR. Binding of monoclonal antibody to the Epstein-Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. J Immunol 1985; 135: 3068–3073.
- 272 Wilson BS, Platt JL, Kay N. Monoclonal antibodies to the 140,000 MW glycoprotein of B lymphocyte membrane (CR2 receptor) initiates proliferation of B cells in vitro. Blood 1985; 66: 824–9.
- 273 Tedder TF, Weis JJ, Clement LT, Fearon DT, Cooper MD. The role of receptors for complement in the induction of polyclonal B-cell proliferation and differentiation. J Clin Immunol 1986; 6: 65–73.
- 274 Fingeroth JD, Heath ME, Ambrosino DM. Proliferation of resting B cells is modulated by CR2 and CR1. Immunol Lett 1989; 21: 291–302.
- 275 Bohnsack JF, Cooper NR. CR2 ligands modulate human B cell activation. J Immunol 1988; 141: 2569–76.
- 276 Petzer AL, Schulz TF, Stauder R., Eigentler A., Myones BL, Dierich MP. Structural and functional analysis of CR2/EBV receptor by means of monoclonal antibodies and limited tryptic digestion. Immunology 1988; 63: 47–53.
- 277 Perri RT, Wilson BS, Kay NE. Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2). Eur J Immunol 1986; 16: 350–5.
- 278 Carter RH, Spycher MO, Ng YC, Hoffman R., Fearon DT. Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol 1988; 141: 457–63.
- 279 Changelian PS, Fearon DT. Tissue specific phosphorylation of complement receptors CR1 and CR2. J Exp Med 1986; 163: 101–15.
- 280 Barel M., Vazquez A., Charriaut C., Aufredou MT, Galanaud P., Frade R. gp 140, the C3d/EBV receptor (CR2), is phosphorylated upon in vitro activation of human peripheral blood lymphocytes. FEBS Lett 1986; 197: 353–6.
- 281 Hatzfeld A., Fischer E., Levesque JP, Perrin R., Hatzfeld J., Kazatchkine MD. Binding of C3 and C3dg to the CR2 complement receptor induces growth of an Epstein-Barr virus-positive human B cell line. J Immunol 1988; 140: 170–5.
- 282 Pernegger G., Schulz TF, Hosp M., Myones BL, Petzer AL, Eigentler A., Böck G., Wick G., Dierich MP. Cell cycle control of a Burkitt lymphoma cell line: responsiveness to growth signals engaging the C3d/EBV receptor. Immunology 1988; 65: 237–41.
- 283 Fleisher TA, Berger M. Immunoregulatory effects of C3 and its major cleavage fragments. Clin Immunol Immunopathol 1984; 33: 391–401.
- 284 Tsokos GC, Berger M., Balow JE. Modulation of human B cell immunoglobulin secretion by the C3b component of complement. J Immunol 1984; 132: 622–6.
- 285 Daha M., Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral lymphocytes induced by anti-C3 receptor antibodies. J Immunol 1984; 132: 1197–1201.
- 286 Weiss L., Delfraisy JF, Vazquez A., Wallon C., Galanaud P., Kazatchkine M. Monoclonal antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. J Immunol 1987; 138: 2988–93.
- 287 Jepsen HH, Teisner B., Folkersen J., Svehag SE. Enhancing effect of autologous human erythrocytes on generation of C3 cleavage products beyond iC3b. Complement 1988; 5: 120–9.
- 288 Kai C., Szigeti R., Åman P., Klein E. Activation of B lymphocytes with human serum-trated zymosan. Cell Immunol 1988; 116: 467–74.
- 289 Lobo PI, Burge JJ. In vitro studies on the immune regulatory role of complement receptors (C3) present on human B lymphocytes. Eur J Immunol 1982; 12: 682–6.
- 290 Sigfusson A., Souhami R. The effect of erythrocyte contamination on poke-weed mitogen induced immunoglobulin synthesis in man. J Immunol Methods 1984; 72: 167–70.
- 291 Ohno R., Kodera Y., Ezaki K., Tanimoto M., Iwamoto K., Yamada K. Inactivation of the mitogenic property of poke-weed mitogen by erythrocytes. J Immunol Methods 1979; 31: 6262.
- 292 Hartmann KP, Raielle A., Schmitt M. β1H stimulates mouse-spleen B lymphocytes, as demonstrated by increased thymidine incorporation and formation of B cell blasts. Immunobiology 1981; 160: 289–92.
- 293 Bötgger EC, Bitter-Suermann D. Complement and the regulation of humoral immune responses. Immunol Today 1987; 8: 261–4.
- 294 Jackson CG, Ochs HD, Wedgwood RJ. Immune response of a patient with deficiency of the fourth component of complement and systemic lupus erythematosus. N Engl J Med 1979; 300: 1124–9.
- 295 Sjöholm AG, Hammarström L., Smith CIE, Kjellman NIM. Immunoglobulin synthesis in a patient with C4-deficiency: Functional immaturity of peripheral blood lymphocytes. Acta Path Microbiol Scand Sect C 1985; 93: 169–73.
- 296 Mascart-Lemone F., Hauptmann G., Goetz J., Duchateu J., Delespesse J., Vary B., Dab I. Genetic deficiency of C4 presenting with recurrent infections and a SLE-like disease. genetic and immunologic studies. Am J Med 1983; 75: 295–304.
- 297 Alper CA, Colten HR, Gear JS, Rabson AR, Rosen FS. Homozygous human C3 deficiency. The role of C3 in antibody production, *C1s-induced vasopermeability and cobra venom factor induced passive hemolysis. J Clin Invest 1976; 57: 222–9.
